Integrated Biopharma Inc's Comment on Supply Chain
The company’s Other Business Lines Segment relies primarily on DSM Nutritional Products LLC as its principal supplier, while its Contract Manufacturing Segment works with multiple suppliers. Effective January 1, 2026, the company entered into development and supply agreements with Herbalife International of America, Inc. and Herbalife International of Luxembourg S.à.R.L., subsidiaries of Herbalife, to develop, manufacture, and supply certain nutritional products. These agreements expire on December 31, 2028, and do not require either party to commit to minimum supply or order volumes. The company also establishes similar agreements with other customers within its contract manufacturing operations.
The manufacturing, processing, formulation, packaging, labeling, and advertising of the company’s products are regulated by federal agencies including the Food and Drug Administration (FDA), Federal Trade Commission (FTC), United States Postal Service, Consumer Product Safety Commission, and the United States Department of Agriculture, as well as various state and local authorities. The company’s vitamin manufacturing facility is regulated by the FDA as a dietary supplement manufacturing facility. Additionally, the company adheres to guidelines from the United States Pharmacopeia Convention, Inc. and other voluntary standards organizations. The company complies with the regulatory framework established by the Dietary Supplement Health and Education Act of 1994.
Integrated Biopharma Inc's Comment on Supply Chain
The company’s Other Business Lines Segment relies primarily on DSM Nutritional Products LLC as its principal supplier, while its Contract Manufacturing Segment works with multiple suppliers. Effective January 1, 2026, the company entered into development and supply agreements with Herbalife International of America, Inc. and Herbalife International of Luxembourg S.à.R.L., subsidiaries of Herbalife, to develop, manufacture, and supply certain nutritional products. These agreements expire on December 31, 2028, and do not require either party to commit to minimum supply or order volumes. The company also establishes similar agreements with other customers within its contract manufacturing operations.
The manufacturing, processing, formulation, packaging, labeling, and advertising of the company’s products are regulated by federal agencies including the Food and Drug Administration (FDA), Federal Trade Commission (FTC), United States Postal Service, Consumer Product Safety Commission, and the United States Department of Agriculture, as well as various state and local authorities. The company’s vitamin manufacturing facility is regulated by the FDA as a dietary supplement manufacturing facility. Additionally, the company adheres to guidelines from the United States Pharmacopeia Convention, Inc. and other voluntary standards organizations. The company complies with the regulatory framework established by the Dietary Supplement Health and Education Act of 1994.
Sources:
Integrated Biopharma Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Integrated Biopharma Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
